欧盟 - 芬兰文 - EMA (European Medicines Agency)

ratiopharm gmbh - paklitakseli - rintojen kasvaimet - antineoplastiset aineet - pazenir monoterapia on tarkoitettu metastasoituneen rintasyövän hoidossa aikuisilla potilailla, jotka eivät ole ensilinjan hoito metastaattinen tauti ja joille vakiintunut antrasykliiniä sisältävä hoito ei ole indisoitu. pazenir yhdessä karboplatiinin kanssa on tarkoitettu ensilinjan hoito ei-pienisoluisen keuhkosyövän hoitoon aikuisille potilaille, jotka eivät ole ehdokkaita mahdollisesti parantava leikkaus ja/tai sädehoito.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

teva b.v. - salmeteroliksinafoaatti, fluticasone propionate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

欧盟 - 芬兰文 - EMA (European Medicines Agency)

midas pharma gmbh - ranibitsumabi - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - silmätautien - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

欧盟 - 芬兰文 - EMA (European Medicines Agency)

teva gmbh - dimetyylifumaraatti - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

欧盟 - 芬兰文 - EMA (European Medicines Agency)

csl behring gmbh - etranacogene dezaparvovec - hemofilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.